The ATM gene and breast cancer: Is it really a risk factor?

Mutation Research - Reviews in Mutation Research

Volumn 462, Issue 2-3, 2000, Pages 167-178

  Angèle, Sandra ^a   Hall, Janet ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Ataxia telangiectasia; Breast cancer; Radiation sensitivity

Indexed keywords

PROTEIN;

ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER RISK; GENE; GENE MUTATION; GENETIC RISK; HETEROZYGOSITY; HUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; RISK FACTOR;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0343618708     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(00)00034-X     Document Type: Article

References (100)

1. Ford D., Easton D.F. The genetics of breast and ovarian cancer. Br. J. Cancer. 72:1995;805-812.
2. Peto J., Collins N., Barfoot R., Seal S., Warren W., Rahman N., Easton D.F., Evans C., Deacon J., Stratton M.R. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl. Cancer Inst. 91:1999;943-949.
3. Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science. 250:1990;1233-1238.
4. Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni Syndrome. Nature. 348:1990;747-749.
5. Swift M., Reitnauer P.J., Morrell D., Chase C.L. Breast and other cancers in families with ataxia telangiectasia. New Engl. J. Med. 316:1987;1289-1294.
6. R.P. Sedgwick, E. Boder, Ataxia-telangiectasia, in: J.M.B.V. De Jong (Ed.), Hereditary Neuropathies and Spinocerebellar Atrophies, Handbook of Clinical Neurology, Vol. 16, Elsevier, Amsterdam, 1991, pp. 347-423.
7. Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P., Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N., Byrd P.J., Taylor A.M.R. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet. 62:1998;334-345.
8. Swift M., Morrell D., Comartie E., Chamberlin A.R., Skolnick M.H., Bishop D.T. The incidence and gene frequency of ataxia telangiectasia in the United States. Am. J. Hum. Genet. 39:1986;573-583.
9. Woods C.G., Bundey S.E., Taylor A.M.R. Unusual features in the inheritance of ataxia telangiectasia. Hum. Genet. 84:1990;555-562.
10. Easton D.F. Cancer risks in A-T heterozygotes. Int. J. Radiat. Biol. 66:1994;S177-182.
11. Gilad S., Bar-Shira A., Harnik R., Shkeday D., Ziv Y., Khosravi R., Brown K., Vanagaite L., Xu G., Frydman M., Lavin M.F., Hill D., Tagle D.A., Shiloh Y. Ataxia-telangiectasia: founder effect among North African Jews. Hum. Mol. Genet. 5:1996;2033-2037.
12. FitzGerald M.G., Bean J.M., Hegde S.R., Unsal H., MacDonald D.J., Harkin D.P., Finkelstain D.M., Isselbacher K.J., Haber D.A. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet. 15:1997;307-310.
13. Telatar M., Teraoka S., Wang Z.J., Chun H.H., Liang T., Castellvibel S., Udar N., Børresen-Dale A.L., Chessa L., Bernatowska-Matuszkiewicz E., Porras O., Watanbe M., Junder A., Concannon P., Gatti R.A. Ataxia telangiectasia - identification and detection of founder-effect mutations on the ATM gene in ethnic populations. Am. J. Hum. Genet. 62:1998;86-97.
14. Chen J., Giesler Birkholtz G., Linblom P., Rubio C., Lindblom A. The role of Ataxia heterozygotes in familial breast cancer. Cancer Res. 58:1998;1376-1379.
15. Savitsky K., Bar-Shira A., Gilard S., Rotman G., Ziv Y., Vanagaite L., A Tagle D., Smith S., Uziel T., Ashkenazi M., Pecker I., Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., Arlett C.F., Miki T., Weissman S., Lovett M., Collins F.S., Shiloh Y. A single ataxia-telangiectasia gene with a product similar to PI 3-kinase. Science. 268:1995;1749-1753.
16. Uziel T., Savitsky K., Platzer M., Ziv Y., Helbitz T., Nehls M., Boehm T., Rosenthal A., Shiloh Y., Rotman G. Genomic organisation of the ATM gene. Genomics. 33:1996;317-320.
17. Shiloh Y. Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu. Rev. Genet. 31:1997;635-662.
18. Lavin M.F. ATM: the product of the gene mutated in ataxia-telangiectasia. Int. J. Biochem. Cell Biol. 31:1999;735-740.
19. Canman C.E., Lim D.S. The role of ATM in DNA damage responses and cancer. Oncogene. 17:1998;3301-3308.
20. Banin S., Moyal L., Shieh S.Y., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677.
21. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
22. Khanna K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 20:1998;398-400.
23. Waterman M.F.J., Stavridi E.S., Waterman J.L.F., Halazonetis T.D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19:1998;175-178.
24. Ko L.J., Prives C. p53: Puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
25. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
26. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 282:1998;1893-1897.
27. Flaggs G., Plug A.W., Dunks A.W., Mundt K.E., Ford J.C., Quiggle M.R.E., Taylor E.M., Westphal C.H., Ashley T., Hoekstra M.F., Carr A.M. ATM-dependant interactions of a mammalian Chk1 homolog with meiotic chromosomes. Curr. Biol. 7:1997;977-986.
28. Kaneko Y., Watanabe N., Morisaki H., Akita H., Fujimoto A., Tominaga K., Terasawa M., Tachibana A., Ikeda K., Nakanishi M. Cell-cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene. 24:1999;3673-3681.
29. Liu V.F., Weaver D.T. The ionizing radiation-induced replication protein A phosphorylation response differs between ataxia telangiectasia and normal human cells. Mol. Cell Biol. 13:1993;7222-7231.
30. Gately D.P., Hittle J.C., Chan G.K., Yen T.J. Characterization of ATM expression, localization and associated DNA-dependent protein kinase activity. Mol. Cell. Biol. 9:1998;2361-2374.
31. Baskaran R., wood L.D., Whitaker L.L., Canman C.E., Morgan S.E., Xu Y., Barlow C., Baltimore D., Wynshaw-Boris A., Kastan M.B., Wang J.Y. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionising radiation. Nature. 387:1997;516-519.
32. Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hoson K., Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., Kufe D., Lavin M.F. Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 387:1997;520-523.
33. Chen G., Yuan S.S., Liu W., Xu Y., Trujillo K., Song B., Cong F., Goff S.P., Wu Y., Arlinghaus R., Baltimore D., Gasser P.J., Park M.S., Sung P., Lee E.Y. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J. Biol. Chem. 30:1999;12748-12752.
34. Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A. ATM gene product phosphorylates Iκβ-α Cancer Res. 57:1997;24-27.
35. Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., Ramsay J., Gatti R.A., Lavin M. Cellular localization of the ataxia-telangeictasia gene product and discrimination between mutated and normal forms. Oncogene. 14:1997;11911-11921.
36. Lim D.S., Kirsch D.G., Canman C.E., Ahn J.H., Ziv Y., Newman L.S., Darnell R.B., Shiloh Y., Kastan M.B. ATM binds to β-adaptin in cytoplasmic vesicles. Proc. Natl. Acad. Sci., U.S.A. 95:1998;10146-10151.
37. Rotman G., Shiloh Y. Ataxia-telangiectasia: is ATM a sensor of oxidative damage and stress? Bioessays. 19:1997;911-917.
38. Barlow C., Dennery P.A., Shigengaga M.K., Smith M.A., Morrow J.D., Roberts L.J. II, Wynshaw-Boris A., Levine R.L. Loss of ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc. Natl. Acad. Sci., U.S.A. 96:1999;9915-9919.
39. Taylor A.M.R. What has the cloning of the ATM gene told us about ataxia telangiectasia? Int. J. Radiat. Biol. 73:1998;365-371.
40. Smith G.C., D'Adda di Fagagna F., Lakin N.D., Jackson S.P. Cleavage and inactivation of ATM during apoptosis. Mol. Cell. Biol. 19:1999;6076-6084.
41. Smith G.C., Cary R.B., Lakin N.D., Hann B.C., Teo S.H., Chen D.J., Jackson S.P. Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM. Proc. Natl. Acad. Sci., U.S.A. 28:1999;11134-11139.
42. Barlow C., Eckhaus M.A., Schäeffer A.A., Wynshaw-Boris A. ATM haplo insufficiency results in increased sensitivity to sublethal doses of ionising radiation in mice. Nat. Genet. 21:1999;359-361.
43. Xu Y., Baltimore D. Dual roles of ATM in the cellular response to radiationand in cell growth control. Genes Dev. 10:1996;2401-2410.
44. Chen P.C., Lavin M.F., Kidson C., Moss D. Identification of ataxia telangiectasia heterozygotes, a cancer prone population. Nature. 274:1978;484-486.
45. Telatar M., Wang Z., Udar N., Liang T., Bernatowska-Matuszkewicz E., Lavin M., Shiloh Y., Concannon P., Godd R.A., Gatti R.A. Ataxia-telangiectasia, mutations in ATM cDNA detected by protein truncation screening. Am. J. Hum. Genet. 62:1998;86-97.
46. Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G., Smith S., Chessa L., Jorgensen T., Harnik R., Frydman M., Sanal O., Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A., Lenoir G., Lavin M.F., Tatsumi K., Wegner R.D., Shiloh Y., Bar-Shira A. Predominance of null mutations in ataxia-telangiectasia. Hum. Mol. Genet. 5:1996;433-439.
47. Ramsay J., Birrell G., Baumann K., Bodero A., Parons P., Lavin M. Radiosensitive melanoma cell line with mutation of the gene on ataxia-telangiectasia. Br. J. Cancer. 77:1998;11-14.
48. Taylor A.M.R., Metcalfe J.A., Thick J., Mak Y.-F. Leukemia and lymphoma in ataxia telangiectasia. Blood. 87:1996;423-438.
49. Vorechovsky I., Luo L., Dyer M.J., Catovsky D., Amlot P.L., Yaxley J.C., Foroni L., Hammarstrom L., Webster A.D., Yuille M.A. Clustering of missense mutations in the ataxia-telangiectasia gene in sporadic cases of T-cell leukemia. Nat. Genet. 17:1997;96-99.
50. Stoppa-Lyonnet D., Soulier J., Laugé A., Dastot H., Garand R., Sigaux F., Stern M.H. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 15:1998;3920-3926.
51. Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., Bar-Shira A., James M.R., Lichter P., Dohner H. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat. Med. 3:1997;1155-1159.
52. Sankaranarayanan K., Chakraborty R. Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers: I. Background. Radiat. Res. 143:1995;121-143.
53. Ramsey J., Birrell G. Normal tissue radiosensitivity in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;339-344.
54. Cole J., Arlett C.F., Green M.H.L., Harcourt S.A., Priestley A., Henderson L., Cole H., James S.E., Richmond F. Comparative human cellular radiosensitivity: II. The survival following gamma-irradiation of unstimulated (G0) T-lymphocytes, T-lymphocyte lines, lymphoblastoid cell lines and fibroblasts from normal donors, from ataxia-telangiectasia patients and from ataxia telangiectasia heterozygotes. Int. J. Radiat. Biol. 54:1988;929-943.
55. Waghray M., Al-Sedairy S., Ozand P.T., Hannan M.A. Study of dose-rate and split-dose effects on the in vitro micronucleus yield in human lymphocytes exposed to X-rays. Int. J. Radiat. Biol. 61:1990;777-784.
56. Weeks D.E., Paterson M.C., Lange K., Andrais B., Davis R.C., Yoder F., Gatti R.A. Assessment of chronic gamma-radiosensitivity as an in vitro assay for heterozygote identification in ataxia-telangiectasia. Radiat. Res. 128:1991;90-99.
57. Lavin M.F., Bennett I., Ramsay J., Gardiner R.A., Seymour G.J., Farrell A., Walsh M. Identification of a potentially radiosensitive subgroup among patients with breast cancer. J. Natl. Cancer Inst. 86:1994;1627-1634.
58. Jones L.A., Scott D., Cowan R., Roberts S.A. Abnormal radiosensitivity of lymphocytes from breast cancer patients with excessive normal tissue damage after radiotherapy; chromosome abberations after low dose-rate irradiation. Int. J. Radiat. Biol. 67:1995;519-528.
59. Brock W.A., Tucker S.L., Geara F.B., Turesson I., Wike J.L., Nyman J., Peters L.J. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1371-1379.
60. West C.M.L., Elyan S.A.G., Berry P., Cowan R., Scott D.A. Comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia-telangiectasia (A-T) and A-T heterozygotes. Int. J. Radiat. Biol. 68:1995;197-203.
61. Scott D., Spreadborough A.R., Roberts S.A. Radiation-induced G2 delay and spontaneous chromosome aberrations in ataxia-telangiectasia homozygotes and heterozygotes. Int. J. Radiat. Biol. 66:1994;S157-163.
62. Scott D., Barber J.B., Spreadborough A.R., Burrill W., Roberts S.A. Increased chromosomal radiosensitivity in breast cancer patients: a comparison of two assays. Int. J. Radiat. Biol. 75:1999;1-10.
63. Roberts S.A., Speadborough A.R., Bulman B., Barber J.B., Evans D.G., Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer? Am. J. Hum. Genet. 65:1999;784-794.
64. Birrell G.W., Ramsay J.R. Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer and ataxia telangiectasia patients. Br. J. Cancer. 72:1995;1096-1101.
65. Negrini M., Rasi D., Hampton G.M., Sabbioni S., Rattan S., L Carter S., Rosenberg A.L., Schwartz G.F., Shiloh Y., Cavenee W.K., Croce C.M. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res. 55:1995;3003-3007.
66. Kerangueven F., Eisinger F., Noguchi T., Allione F., Wargniez V., Eng C., Padberg G., Theillet C., Jacquemier J., Longy M., Sobol H., Birnbaum D. Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene. 14:1997;339-347.
67. Laake K K., Ødegård A., Andersen T.I., Bukholm I.K., Kåresen R., Nesland J.M., Ottestad L., Shiloh Y., Børresen-Dale A.L. Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a distal and close to ATM. Genes, Chromosome Cancer. 18:1997;175-180.
68. Rio P.G., Pernin D., Bay J.O., Albuisson E., Kwiatkowski F., Delatour M., Bernard-Gallon D., Bignon Y.J. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int. J. Oncol. 13:1998;849-853.
69. di Iasio M.G., Calin G., Tibiletti M.G., Vorechovsky I., Benediktsson K.P., Taramelli R., Barbanti-Brodano G., Negrini M. Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region. Oncogene. 18:1999;1635-1638.
70. Launonen V., Laake K., Huusko P., Niederacher D., Beckmann M.W., Barkardottir R.B., Geirsdottir E.K., Gudmundsson J., Rio P., Bignon Y.J., Seitz S., Scherneck S., Bieche I., Champème M.H., Birnbaum D., White G., Varley J., Sztán M., Olah E., Osorio A., Benitez J., Spurr N., Velikonja N., Peterlin B., Borg A., Cleton-Jansen A.M., Devilee P., Bloigu R., Lidereau R., Børresen-Dale A.L., Winqvist R. The breast cancer somatic genetics consortium: European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Br. J. Cancer. 80:1999;879-882.
71. Izatt L., Greenman J., Hodgson S., Ellis D., Watts S., Scott G., Jacobs C., Liebmann R., Zvelebi M.J., Mathew C., Solomon E. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes, Chromosomes Cancer. 26:1999;286-294.
72. Monaco C., Negrini M., Sozzi G., Veronese M.L., Vorechovsky I., Godwin A.K., Croce C.M. Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23. Genomics. 46:1997;217-222.
73. Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H., Elledge S.J. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 277:1997;1497-1501.
74. Savitsky K., Ziv Y., Bar-Shira A., Gilad S., Tagle D.A., Smith S., Uziel T., Sfez S., Nahmias J., Sartiel A., Eddy R.L., Shows T.B., Povey S., Collins F.S., Shiloh Y., Rotman G. A human gene encoding a putative DEAD-box RNA helicase at 11q22-23. Genomics. 33:1996;199-206.
75. Clarke R.A., Kairouz R., Watters D., Lavin M.F., Kearsley J.H., Lee C.S. Upregulation of ATM in sclerosing adenosis of the breast. J. Clin. Pathol. Mol. Pathol. 51:1998;224-226.
76. Waha A., Sturne C., Kessler A., Koch A., Kreyer E., Fimmers R., Wiestler O.D., von Deimling A., Krebs D., Schmutzler R.K. Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. Int. J. Cancer. 78:1998;306-309.
77. Janin N., Andrieu N., Ossian K., Laugé A., Croquette M.-F., Griscelli C., Debré M., Bressac-de-Paillerets B., Aurias A., Stoppa-Lyonnet D. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br. J. Cancer. 80:1999;1042-1045.
78. Bebb D.G., Yu Z., Chen J., Telatar M., Gelmon K., Phillips N., Gatti R.A., Glickman B.W. Absence of mutations in the ATM gene in 47 cases of sporadic breast cancer. Br. J. Cancer. 80:1999;1979-1981.
79. Athma P., Rappaport R., Swift M. Molecular genotyping shows that the ataxia telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 92:1996;130-134.
80. Bishop D.T., Hopper J. AT-tributable risks? Nat. Genet. 15:1997;226.
81. Shayeghi M., Seal S., Regan J., Collins N., Barfoot R., Ashton A., Moohan M., Wooster R., Owen E., Bliss J.M., Stratton M.R., Yarnold J. Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br. J. Cancer. 78:1998;922-927.
82. Larson G., Zhang G., Ding S., Foldenauer K., Udar N., Gatti R.A., Neuberg D., Lunetta K.L., Ruckdeschel J.C., Longmate J., Flanagan S., Krontiris T.G. An allelic variant at the ATM locus is implicated in breast cancer susceptibility. Genet. Test. 1:1997;165-170.
83. Vorechovsky I., Ortmann E., Steinmann D., Dörk T. Missense mutations at ATM gene and cancer risk. Lancet. 353:1999;1276.
84. Lavin M.F., Concannon P., Gatti R.A. 8th International Workshop on Ataxia-Telangiectasia (ATW8). Cancer Res. 59:1999;3845-3849.
85. Feunteun J. Breast cancer and genetic instability. Mol. Med. Today. 4:1998;263-267.
86. Chen J.-J., Silver D., Cantor S., Livingstone D.M., Scully R. BRCA1, BRCA2 and RAD51 operate in common DNA damage response pathway. Cancer Res. 59:1999;1752s-1756s.
87. Cortez D., Wang Y., Qin J., Elledge S.J. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science. 286:1999;1162-1166.
88. Hall J., Angèle S. Radiation. DNA damage and cancer. Mol. Med. Today. 5:1999;157-164.
89. Swift M., Morrell D., Massey R.B., Chase C.L. Incidence of cancer in 161 families affected by ataxia telangiectasia. New Engl. J. Med. 325:1991;1831-1836.
90. Pippard E.C., Hall A.J., Barker D.J., Bridges B.A. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 48:1988;2929-2932.
91. Børresen A.L., Andersen T.I., Tretli S., Heiberg A., Møller P. Breast cancer and other cancers in Norwegian families with ataxia telangiectasia. Genes, Chromosome Cancer. 2:1990;339-402.
92. Inskip H.M., Kinlen L.J., Taylor A.M.R., Wood C.G., Arlett C.F. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br. J. Cancer. 79:1999;1301-1307.
93. Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B., Croce C.M., Hammarström L.L. ATM mutations in cancer families. Cancer Res. 56:1996;4130-4133.
94. Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarström L.L., Webster D.B., Zaloudik J., Barbanti-Brodano G., James M., Tusso G., Croce C.M., Negrini M. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumours reveals no evidence for mutation. Cancer Res. 56:1996;2726-2732.
95. Ramsay J., Birrell G., Lavin M. Breast cancer and radiotherapy in ataxia telangiectasia heterozygote. Lancet. 347:1996;1627.
96. Appleby J.M., Barber J.B.P., Levine E., Varley J.M., Taylor A.M.R., Stankovic T., Heighway J., Warren C., Scott D. Absence of mutations in ATM gene in breast cancer patients with severe responses to radiotherapy. Br. J. Cancer. 76:1997;1546-1549.
97. Bay J.O., Grancho M., Pernin D., Presneau N., Rio P., Tchirkov A., Uhrammer N., Verrelle P., Gatti R.A., Bignon Y.J. No evidence for constitutional ATM mutation in breast/gastric cancer families. Int. J. Oncol. 12:1998;1385-1890.
98. Ramsay J., Birrell G., Lavin M. Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. Radiother. Oncol. 47:1998;125-128.
99. Oppitz U., Bernthaler U., Schindler D., Sobeck A., Hoehn H., Platzer M., Rosenthal A., Flentje M. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int. J. Rad. Oncol. Biol. Phys. 44:1999;981-988.
100. Varghese S., Schmidt-Ullrich R.K., Dritschilo A., Jung M. Enhanced radiation late effects and cellular radiation sensitivity in an ATM heterozygous breast cancer patient. Radiat. Oncol. Invest. 7:1999;231-237.